Microbion
Microbion Corporation is a clinical-stage biopharmaceutical company developing pravibismane (MBN-101), a first-in-class antimicrobial that halts bacterial metabolism and eradicates biofilms. Topical, intraoperative, and inhaled formulations target diabetic foot ulcers, orthopedic implant infections, and respiratory diseases (cystic fibrosis and NTM).
- Company typePrivate
- Founded2016
- HeadquartersBozeman, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Microbion does
Microbion Corporation is a clinical-stage biopharmaceutical company developing pravibismane (MBN-101), the first member of a new anti-infective drug class known as microbial bioenergetic inhibitors or the bismane class, as recognized by the World Health Organization's assignment of the International Nonproprietary Name in October 2019. The lead candidate works through a novel mechanism that disrupts bacterial adenosine triphosphate (ATP) production and proton synthesis, halting microbial cellular metabolism rather than targeting a single bacterial pathway. The drug uniquely eradicates bacterial biofilms, the protective structures that often shield chronic infections from conventional antibiotic therapy. The company is headquartered in Bozeman, Montana, with co-located operations via subsidiary Microbion Pharma Corp. in Vancouver, British Columbia, and employs 11-50 people.
Microbion is advancing pravibismane across three indications and delivery routes: a topical hydrogel suspension for moderately infected diabetic foot ulcers (Phase 2, positive topline results announced November 2024 with 52.6% complete wound closure as sole pharmacologic intervention); a local/intraoperative formulation administered during surgery for post-surgical orthopedic implant infections (Phase 2); and an inhaled formulation in preclinical development for chronic pulmonary nontuberculous mycobacterial (NTM) infections and cystic fibrosis pulmonary infections. The company holds three issued US patents (Nos. 11,207,288; 11,324,715; 11,464,749) covering composition and methods of treatment with protection extending through approximately 2039, plus an inbound licensing agreement with NYU Langone Health consolidating rights to jointly developed bismuth-thiol technology. The FDA has granted Qualified Infectious Disease Product (QIDP), Fast Track, and two Orphan Drug Designations to pravibismane, layering cumulative market exclusivity.
The pre-approval business model is grant- and equity-funded R&D; upon regulatory approval, Microbion intends to commercialize through standard pharmaceutical distribution channels including hospital pharmacies and specialty pharmacies, targeting healthcare providers treating chronic wound infections, orthopedic infections, and chronic respiratory infections. Capital sources include a US$25 million Series A in 2017 from Quark Venture and GF Securities (Global Health Sciences Venture Fund), over US$22 million in non-dilutive grants from CARB-X, the Cystic Fibrosis Foundation, NIH, the US Department of Defense, and the US Navy/MTEC, plus a strategic equity-linked manufacturing partnership with bismuth API specialist 5N Plus signed in January 2021. The company has no approved product and reports no revenue.
Microbion firmographics
Firmographics- Name
- Microbion
- Legal name
- Microbion Corporation
- Website
- https://microbioncorp.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Microbion Corporation is a clinical-stage biopharmaceutical company developing pravibismane (MBN-101), a first-in-class antimicrobial that halts bacterial metabolism and eradicates biofilms. Topical, intraoperative, and inhaled formulations target diabetic foot ulcers, orthopedic implant infections, and respiratory diseases (cystic fibrosis and NTM).
- Ownership category
- akta.pro rank
Microbion industry classification
Industry- Product category
- Anti-infective Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where Microbion is headquartered
LocationHeadquarters
- HQ city
- Bozeman
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Microbion business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Microbion is a clinical-stage biopharmaceutical company. Revenue will be generated through sales of pravibismane upon regulatory approval for treatment of diabetic foot ulcer infections, orthopedic implant infections, and respiratory infections (CF and NTM).
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Microbion product offering
Product offeringCore offering
Microbion is a clinical-stage biopharmaceutical company developing pravibismane (MBN-101), the first in a new class of anti-infective drugs called microbial bioenergetic inhibitors. The company formulates pravibismane in topical, intraoperative/local, and inhaled dosage forms targeting diabetic foot ulcer infections, orthopedic implant infections, and chronic respiratory infections in cystic fibrosis and NTM patients. The drug's mechanism disrupts bacterial ATP production and eradicates biofilms that drive chronic and antibiotic-resistant infections.
Product overview
Microbion is a clinical-stage pharmaceutical company developing pravibismane (MBN-101), the first product in a new class of anti-infective drugs called microbial bioenergetic inhibitors. The company offers pravibismane in multiple formulations: topical pravibismane (hydrogel suspension) for diabetic foot ulcer infections, local/intraoperative pravibismane for orthopedic implant infections, and inhaled pravibismane for respiratory infections including cystic fibrosis and NTM lung infections. All formulations leverage pravibismane's novel mechanism of action that halts microbial cellular metabolism and eradicates biofilms.
Differentiator
Problem solved
Functional benefit
Brands
- Pravibismane: Lead therapeutic candidate; first in a new class of anti-infective drugs with broad-spectrum activity and novel mechanism of action that halts microbial cellular metabolism
- MBN-101
Products and services
- Pravibismane (MBN-101) The lead therapeutic candidate and first in a new class of anti-infective drugs with broad-spectrum activity and a novel mechanism of action that halts microbial cellular metabolism. Pravibismane prevents and eradicates biofilms that contribute to chronic infection and facilitate antibiotic-resistance.
- Topical Pravibismane Hydrogel Hydrogel suspension formulation of pravibismane applied topically 3 times per week to treat moderately infected diabetic foot ulcers. Granted FDA QIDP and Fast Track designations. Phase 1b showed ~3-fold reduction in ulcer size (85% vs 30% placebo) and ~6-fold reduction in amputation rate (2.6% vs 15.4% placebo).
- Local/Intraoperative Pravibismane Sterile hydrogel suspension formulation of pravibismane administered intraoperatively during surgery for orthopedic implant infections. Applied directly to bone and exposed hardware, providing dual antimicrobial and anti-biofilm effects to enhance bacterial eradication at the infection site.
- Inhaled Pravibismane Inhalation formulation of pravibismane for treatment of chronic lung diseases including non-tuberculous mycobacteria (NTM) infections and cystic fibrosis-related pulmonary infections. Has received Orphan Drug Designation from US FDA for both indications.
Quantifiable outcome
- Phase 2 study demonstrated 52.6% complete wound closure rate with pravibismane as sole pharmacologic intervention
- +2 more outcomes
Companies that use Microbion
Customer profileSegments3 records
Ideal customer profiles4 records
Microbion technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Microbion partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- CUBRC, Inc.coreStrategic partnership with Buffalo-based not-for-profit research company for up to $2.1 million funding from US Navy through Medical Technology Enterprise Consortium (MTEC). Funding supports exploratory Phase 2 proof-of-concept trial in patients hospitalized for moderate to severe diabetic foot ulcer infection.
- 5N PluscoreStrategic relationship for development, manufacturing and commercial drug substance supply. 5N Plus, as the world's leading producer of Bismuth-based API compounds, assumed responsibility for manufacturing Bismuth-based Active Pharmaceutical Ingredients required in Microbion's drug products including pravibismane. 5N Plus took an equity stake in Microbion as part of the agreement.
- NYU Langone HealthcoreLitigation settlement agreement including license agreement where Microbion was assigned NYU Langone's rights to certain patents related to bismuth-thiol technology jointly developed by Dr. Brett Baker of Microbion and Dr. Philip Domenico of NYU Langone. Microbion and NYU Langone agreed that Drs. Baker and Domenico are joint inventors of 3 patents.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Microbion competitors and assessment
Company assessmentDirect peers
- Iterum Therapeutics: Clinical-stage anti-infective developer focused on oral sulopenem for complicated UTIs and other resistant infections. Closely comparable to Microbion as a small, publicly listed anti-infective company advancing a novel agent through late-stage trials against resistant pathogens.
- Cidara Therapeutics: Clinical-stage anti-infective company developing antifungal and antibacterial agents, including novel CD101 for invasive fungal infections. Comparable as a late-clinical anti-infective peer pursuing hospital-channel commercialization.
- Nabriva Therapeutics: Developer of lefamulin, a first-in-class pleuromutilin antibiotic approved for community-acquired bacterial pneumonia. Comparable small-cap anti-infective company with a novel mechanism and hospital-focused commercialization.
- ContraFect Corporation: Clinical-stage anti-infective company developing direct lytic agents (lysins) and other molecules that target resistant bacteria and biofilms. Direct comparability due to antibiofilm mechanism and similar hospital-infection focus.
- Destiny Pharma: Clinical-stage developer of novel antimicrobial drugs, including XF-73 for the prevention of post-surgical staphylococcal infections. Comparable as a small anti-infective company with a novel mechanism targeting resistant Gram-positive bacteria.
- Spero Therapeutics: Clinical-stage anti-infective company developing tebipenem HBr for complicated UTIs and SPR206 for MDR Gram-negative infections. Directly comparable late-clinical anti-infective peer targeting resistant pathogens.
- Melinta Therapeutics: Commercial-stage antibiotics company with delafloxacin (Baxdela) and a pipeline of agents targeting MDR bacterial infections. Comparable commercial-stage anti-infective peer with hospital-channel focus.
Broad incumbents
- Paratek Pharmaceuticals: Commercial-stage anti-infective company with Nuzyra (omadacycline) approved for community-acquired pneumonia and skin infections. Comparable as a broader anti-infective player with approved and pipeline assets in similar hospital indications.
- Tetraphase Pharmaceuticals: Developer of Xerava (eravacycline), an approved fluorocycline antibiotic for complicated intra-abdominal infections, acquired by La Jolla Pharmaceutical Company. Comparable commercial-stage anti-infective peer with a recently approved novel antibiotic.
- Pfizer: One of the world's largest anti-infective developers and commercializers, with a broad portfolio spanning vaccines, antivirals, and antibiotics. Relevant as a potential strategic acquirer or licensing partner for Microbion's first-in-class anti-infective asset.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Microbion social profiles
Digital presenceMicrobion compliance and trust
Trust signalCompliance4 records
Microbion financial estimates
Financial estimateRevenue estimate
Valuation estimate
Microbion leadership team
Management profileNumber of profiles
Profiles8 records
Microbion subsidiaries and ownership
Company hierarchySubsidiaries1 record
Microbion funding detail
Funding detailFunding overview
Funding rounds9 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Microbion M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Microbion
What does Microbion do?
Microbion is a clinical-stage biopharmaceutical company developing pravibismane (MBN-101), the first in a new class of anti-infective drugs called microbial bioenergetic inhibitors. The company formulates pravibismane in topical, intraoperative/local, and inhaled dosage forms targeting diabetic foot ulcer infections, orthopedic implant infections, and chronic respiratory infections in cystic fibrosis and NTM patients. The drug's mechanism disrupts bacterial ATP production and eradicates biofilms that drive chronic and antibiotic-resistant infections.
Is Microbion a public or private company?
Microbion is a private company. It is classified as venture growth investor backed and is currently operating.
When was Microbion founded?
Microbion was founded in 2016. It employs 11 to 50 people.
Where is Microbion based?
Microbion is headquartered in Bozeman, United States, in the North America region.
How does Microbion make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Microbion's main competitors?
Direct peers on record are Iterum Therapeutics, Cidara Therapeutics, Nabriva Therapeutics, ContraFect Corporation, Destiny Pharma, Spero Therapeutics and Melinta Therapeutics. Broad incumbents are Paratek Pharmaceuticals, Tetraphase Pharmaceuticals and Pfizer.
Does Microbion have an API?
No public API is recorded for Microbion.
What industry is Microbion in?
Microbion's product category is Anti-infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.